Liabilities / Assets
57th percentile
Tied with the lowest-debt nonprofits in its peer group.
Siviq Scores
Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.
0.00x
Liabilities / Revenue
57th percentile
Tied with the lowest-debt nonprofits in its peer group.
Net Margin
97th percentile
Higher net margin than 97% of similar nonprofits.
Top Officer Pay
Score unavailable
This filing does not contain officer compensation rows.
Asset Growth
100th percentile
Faster asset growth than 100% of similar nonprofits.
Revenue Growth
Score unavailable
A valid growth rate could not be computed from the available filing history.
Balance Sheet
Assets
Up$127,399
Up $127,398 (+12739800%) from 2018
Net Assets
Up$127,399
Up $127,399 from 2018
Liabilities
Flat$0
Flat from 2018
Revenue And Expenses
Revenue
Up$150,326
Up $150,326 from 2018
Expenses
Up$22,927
Up $22,927 from 2018
Net Income
Up$127,399
Up $127,399 from 2018
Historical Trend
Filing Detail Status
This 2019 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.
Jump To
Filing Snapshot
- Filing Period
- Jul 1, 2018 to Jun 30, 2019
Mission and Program Overview
Mission
Our mission is to connect families, resources, and the medical community to advance research for a cure to ddx3x gene mutations. Our ultimate goal over the coming years is to accelerate brain function in individuals affected by ddx3x through advances in gene therapy and pharmaceuticals.
Document Assets
No mirrored PDF or thumbnail assets are attached yet.
Filings
Displayed year
2019 • Form 990Summary only. Only limited summary data is available for this year.
- Assets
- $127,399
- Liabilities
- $0
- Net assets
- $127,399
- Revenue
- $150,326
- Expenses
- $22,927
- Net income
- $127,399